Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting KRAS mutant lung cancer: light at the end of the tunnel
Matthias Drosten, Mariano Barbacid
Molecular Oncology (2021) Vol. 16, Iss. 5, pp. 1057-1071
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 994-1017
Open Access | Times Cited: 74
Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4562-4562
Open Access | Times Cited: 68
Dynamic regulation of RAS and RAS signaling
Walter Kölch, Dénes Berta, Edina Rosta
Biochemical Journal (2023) Vol. 480, Iss. 1, pp. 1-23
Open Access | Times Cited: 53
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Marina Salmón, Ruth Álvarez, Coral Fustero‐Torre, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 7
Open Access | Times Cited: 33
Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer
Yu Zhang, Liang Liu, Jinpeng Pei, et al.
Oncogene (2024) Vol. 43, Iss. 9, pp. 668-681
Open Access | Times Cited: 8
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote de Cabo, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 527-548
Closed Access | Times Cited: 6
Unravelling the Triad of Lung Cancer, Drug Resistance, and Metabolic Pathways
Pratik Mohanty, Babita Pande, Rakesh Kumar Acharya, et al.
Diseases (2024) Vol. 12, Iss. 5, pp. 93-93
Open Access | Times Cited: 5
Multi-Omics Analysis Reveals Immune Infiltration and Clinical Significance of Phosphorylation Modification Enzymes in Lung Adenocarcinoma
Deyu Long, Yanheng Ding, Peng Wang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1066-1066
Open Access
The NRF2 antagonist ML385 inhibits PI3K‐mTOR signaling and growth of lung squamous cell carcinoma cells
Lili Ji, Nadeem Moghal, Xinru Zou, et al.
Cancer Medicine (2022) Vol. 12, Iss. 5, pp. 5688-5702
Open Access | Times Cited: 20
RASGRP2 is a potential immune-related biomarker and regulates mitochondrial-dependent apoptosis in lung adenocarcinoma
Yongting Liu, Yanhong Ouyang, Ziyang Feng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
R. Rosell, Jordi Codony‐Servat, Jessica González, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 195, pp. 104228-104228
Open Access | Times Cited: 12
Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node
Rossella Scardaci, Ewa Berlinska, Pietro Scaparone, et al.
Molecular Oncology (2024) Vol. 18, Iss. 6, pp. 1355-1377
Open Access | Times Cited: 4
Necroptosis Identifies Novel Molecular Phenotypes and Influences Tumor Immune Microenvironment of Lung Adenocarcinoma
Chen Zhao, Kewei Xiong, Abdalla Adam, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type
Kyu‐Young Oh, Ji‐hoon Kim, Sung‐Dae Cho, et al.
Genes Chromosomes and Cancer (2022) Vol. 61, Iss. 8, pp. 481-490
Closed Access | Times Cited: 10
KRAS inhibitors: going noncovalent
Matthias Drosten, Mariano Barbacid
Molecular Oncology (2022) Vol. 16, Iss. 22, pp. 3911-3915
Open Access | Times Cited: 10
Targeting Ras with protein engineering
Atílio Tomazini, Julia M. Shifman
Oncotarget (2023) Vol. 14, Iss. 1, pp. 672-687
Open Access | Times Cited: 5
Let-7a Downregulation Accompanied by KRAS Mutation Is Predictive of Lung Cancer Onset in Cigarette Smoke–Exposed Mice
Alessandra Pulliero, Luca Mastracci, Letizia Tarantini, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11778-11778
Open Access | Times Cited: 5
Sequential virtual screening collaborated with machine-learning strategies for the discovery of precise medicine against non-small cell lung cancer
Muthu Kumar Thirunavukkarasu, V. Shanthi, K. Ramanathan
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 2, pp. 615-628
Closed Access | Times Cited: 4
Identification of tumor heterogeneity associated with KRAS/TP53 co-mutation status in lung adenocarcinoma based on single-cell RNA sequencing
Yinghui Ye
American Journal of Cancer Research (2024) Vol. 14, Iss. 2, pp. 655-678
Open Access | Times Cited: 1
Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors
Fernando Fernández-García, Ana Fernández‐Rodríguez, Coral Fustero‐Torre, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 36
Closed Access | Times Cited: 1
KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening
Constanza Tapia Contreras, Jonas Dominik Falke, Dana‐Magdalena Seifert, et al.
Molecular Oncology (2024)
Open Access | Times Cited: 1
KRAS Inhibitors and Target Engagement Technology: From Undruggable to Druggable Targets in Cancer Therapeutics
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 5, pp. 752-754
Open Access | Times Cited: 5
Comprehensive analysis of histone methylation modification regulators for predicting prognosis and drug sensitivity in lung adenocarcinoma
Ying Ye, Li Li, Qinjin Dai, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 3
Identification and validation of an inflammatory response-related signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer
Xuelei Hu, Tengfei Jiang, Jinxiang Wang
Research Square (Research Square) (2024)
Open Access
Anoikis-related subtype and prognosis analyses based on bioinformatics, and an expression verification of ANGPTL4 based on experiments of lung adenocarcinoma
Xiaojian Shen, Jing Xie, Shu Liu, et al.
Journal of Thoracic Disease (2024) Vol. 16, Iss. 8, pp. 5361-5378
Open Access
Page 1 - Next Page

Scroll to top